''List of substances'' and ''Limitations'' to read as follows:

§ 178.3400 Emulsifiers and/or surface active agents.

(c) * * *

* * * * *

List of substances	Limitations
* * *	* * * *
Sulfosuccinic acid 4-ester with polyethylene glycol nonylphenyl ether, disodium salt (alcohol moiety produced by condensation of 1 mole nonylphenol and an average of 9–10 moles of ethylene oxide) (CAS Reg. No. 9040–38–4).	For use only at levels not to exceed 5 percent by weight of the total coating monomers used in the emulsion polymerization of polyvinyl acetate and vinyl-acrylate copolymers intended for use as coatings for paper and paperboard.
* * *	* * * *

* * * * *

Dated: May 15, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–14296 Filed 5–29–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 520

Animal Drugs, Feeds, and Related Products; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for an approved new animal drug application (NADA) from Deprenyl Animal Health, Inc., to Pfizer, Inc.

EFFECTIVE DATE: June 1, 1998.

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: Deprenyl Animal Health, Inc., 7101 College Blvd., suite 580, Overland Park, KS 66210, has informed FDA that it has transferred the ownership of, and all rights and interests in, the approved NADA 141–080 (selegiline hydrochloride tablets) to Pfizer, Inc., 235 East 42d St., New York, NY 10017. The agency is amending 21 CFR 510.600(c)(1) and (c)(2) to remove the sponsor name for Deprenyl Animal Health, Inc., because the firm no longer is the holder of any approved NADA's. The agency is also amending 21 CFR 520.2098 to reflect the change of sponsor.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for ''Deprenyl Animal Health, Inc.''; and in the table in paragraph (c)(2) by removing the entry for ''063248''.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.2098 [Amended]

4. Section 520.2098 *Selegiline hydrochloride tablets* is amended in paragraph (b) by removing ''063248'' and by adding in its place ''000069''.

Dated: May 12, 1998.

Andrew J. Beaulieu,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–14299 Filed 5–29–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Lufenuron Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for subcutaneous use of lufenuron suspension in cats for control of flea populations.

EFFECTIVE DATE: June 1, 1998.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1612.

SUPPLEMENTARY INFORMATION: Novartis Animal Health US, Inc., P.O. Box 26402, Greensboro, NC 27404–6402, is the sponsor of NADA 141–105 that provides for the subcutaneous use of Program™ (lufenuron) 10 percent sterile suspension for cats for the control of flea populations. The drug is limited to use by or on the order of a licensed veterinarian. The NADA is approved as of March 13, 1998, and the regulations are amended by adding § 522.1289 to reflect the approval. The basis of